Meanwhile, ginsenoside Rb3 was screened as a novel inhibitor of KMO, and it was also found to have an excellent therapeutic effect on MI injury through regulating KMO mediated mitochondrial fusion and fission, which showed the great clinical potential to be seen as a candidate for the treatment of clinical MI (Figure 9). The gene discussed is KMO; the disease is myocardial infarction.